| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -22,392 | -102,198 | -93,841 | NaN |
| Stock-based compensation expense | 3,007 | 3,903 | 10,147 | NaN |
| Depreciation | 12 | 19 | 277 | NaN |
| Amortization of debt issuance costs and discounts | 2,362 | 2,445 | 8,101 | NaN |
| Interest expense added to debt principal | 6,911 | 6,258 | NaN | NaN |
| Net amortization of premiums and discounts on investments | -2 | 9 | 401 | NaN |
| Loss (gain) on extinguishment of debt | NaN | -62,365 | 0 | NaN |
| Change in fair value of embedded derivatives and common stock warrants | 16,481 | -9,889 | 10,596 | NaN |
| Accounts receivable, net | -2,821 | -5,699 | 1,111 | NaN |
| Inventory | -439 | 72 | -773 | NaN |
| Prepaid expenses and other assets | -659 | 93 | -4,219 | NaN |
| Operating lease right-of-use assets | -139 | -132 | -1,204 | NaN |
| Accounts payable | 276 | -1,389 | 285 | NaN |
| Accrued expenses and other liabilities | -257 | 1,441 | 17,622 | NaN |
| Operating lease liabilities | -226 | -218 | -220 | NaN |
| Net cash used in operating activities | -22,728 | -11,828 | -63,541 | NaN |
| Proceeds from maturities of investments | 3,200 | 5,000 | 38,378 | NaN |
| Purchases of investments | NaN | 0 | 0 | NaN |
| Purchases of property and equipment | NaN | 0 | 0 | NaN |
| Net cash provided by investing activities | 3,200 | 5,000 | 38,378 | NaN |
| Proceeds from convertible debt | NaN | 15,000 | NaN | NaN |
| Proceeds from senior secured term loan | NaN | 12,250 | 0 | NaN |
| Proceeds from issuance of common stock under open market sale agreement | 20,233 | NaN | NaN | NaN |
| Proceeds from issuance of common stock and warrants in private placement offering | 30,000 | 8,750 | NaN | NaN |
| Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan | NaN | 405 | 356 | NaN |
| Payment of debt issuance costs | NaN | NaN | 0 | NaN |
| Payment of convertible debt | NaN | 250 | NaN | NaN |
| Payment of deferred royalty obligation | NaN | 0 | 0 | NaN |
| Payment of equity issuance costs | 431 | 6,463 | NaN | NaN |
| Net cash provided by financing activities | 49,802 | 29,692 | 356 | NaN |
| Long-term restricted cash | NaN | NaN | NaN | 350 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 2 | 5 | 15 | NaN |
| Short-term restricted cash | NaN | NaN | NaN | 0 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 30,276 | 22,869 | -24,792 | NaN |
| Cash and cash equivalents | NaN | NaN | NaN | 38,725 |
| Cash, cash equivalents and restricted cash at beginning of period | 60,891 | 38,022 | 39,075 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 91,167 | 60,891 | 38,022 | 39,075 |
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI)